Transplant Genomics has announced a collaboration with the Mayo Clinic to develop, validate, and commercialize diagnostic tests enabling personalized immunosuppression for solid organ transplant recipients. As part of the multiyear collaboration, Mayo Clinic will make an investment in Transplant Genomics for an undisclosed amount. Additionally, both companies with work together on co-development of new tests and technologies for additional targets, including exploratory studies in heart and
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
